Plain-English translation of NCT06549270 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying why about 4 in 10 people with resistant migraines don't get relief from monoclonal antibodies () — a newer type of migraine preventive medication. This trial will collect blood samples from migraine patients before and after they start this medication to look for biological differences that might explain why some people benefit while others don't.
Even though this medication works well for many people with hard-to-treat migraines, it fails to help about 40% of patients. Researchers believe these non-responders may have different biological patterns that make them resistant to this particular treatment approach, and identifying those patterns could lead to new, better treatment options.
You likely qualify if…
You likely don't qualify if…
You will have blood samples taken at the start of the study (before you begin the migraine medication) and again after 3 months of treatment. Researchers will then compare your blood work based on whether you respond well to the medication (50% or more reduction in migraine days) or do not respond well (less than 50% reduction). The study will examine multiple biological markers in your blood to identify patterns that may explain treatment response.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Italy
Sponsor
IRCCS National Neurological Institute "C. Mondino" Foundation
Collaborators
University of L'Aquila
Enrollment target
~100 participants
Started
May 2023
Primary completion
February 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in September 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Roberto De Icco
IRCCS National Neurological Institute "C. Mondino" Foundation
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.